HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Factor VIII (Coagulation Factor VIII)

Subscribe to New Research on Factor VIII

Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.

Also Known As:

Coagulation Factor VIII; Blood Coagulation Factor VIII; F VIII-C; Factor VIIIC; Hyate-C; Hyatt-C; Speywood Brand of Porcine Factor VIII Preparation; F VIII C; Hyate C; HyateC; Hyatt C; HyattC; Factor VIII Clotting Antigen; Factor VIII Coagulant Antigen; Factor VIII Procoagulant Activity; Thromboplastinogen; Blood-coagulation factor VIII, complex

Networked: 5450 relevant articles (202 outcomes, 466 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Franchini, Massimo: 39 articles (12/2015 - 11/2003)
2.	Oldenburg, J: 39 articles (09/2015 - 01/2000)
3.	Oldenburg, Johannes: 26 articles (10/2015 - 06/2002)
4.	Mannucci, Pier Mannuccio: 25 articles (12/2015 - 05/2002)
5.	Berntorp, Erik: 24 articles (11/2015 - 02/2003)
6.	Mannucci, P M: 24 articles (09/2014 - 01/2000)
7.	Shima, Midori: 22 articles (11/2015 - 03/2002)
8.	Lacroix-Desmazes, Sébastien: 22 articles (02/2015 - 02/2002)
9.	Shima, M: 21 articles (10/2015 - 07/2000)
10.	Rosendaal, F R: 21 articles (10/2015 - 01/2000)

Related Diseases

1.	Hemophilia A (Haemophilia) 03/01/2013 - "In patients with hemophilia A, outcomes have improved dramatically over the last few decades due to several advances in care, including the availability of factor VIII (FVIII) concentrates. " 01/01/2009 - "Because factor VIII (FVIII) inhibitor formation is the most serious treatment-related complication for hemophilia A patients, we tested the efficacy of anti-CD3 to prevent FVIII inhibitor formation in hemophilia A BALB/c and C57BL/6 mice. " 05/15/1989 - "Factor VIII-CVP therapy is highly effective in the eradication of factor VIII inhibitor in nonhemophiliac patients but not in patients with hemophilia." 11/01/1999 - "These results suggest that PE is very effective in treating factor VIII inhibitor-positive acquired hemophilia." 01/01/2013 - "Prophylaxis may be beneficial for patients with severe haemophilia A who have developed inhibitors to factor VIII. The aim of this study was to determine physicians' preferences for medication attributes in the prophylactic treatment of this patient population. "
2.	Hemorrhage 05/01/2004 - "Porcine factor VIII was highly effective in both treating acute bleeding episodes and preventing bleeding after surgery." 12/01/1985 - "These data indicate that isolated F.VIII:C promptly complexes with vWF and in this form is highly effective in controlling hemophilic hemorrhages with good survival in plasma. " 02/01/2000 - "As a result, the titer of factor VIII inhibitor was markedly improved, but the reduced activity of factor VIII was continued and re-bleeding around neck was observed. " 01/01/2015 - "Successful immunoadsorption of life-threatening bleeding in factor VIII inhibitor disease, but no long-term remission with anti-CD20 treatment." 04/01/2000 - "Effective treatment of bleeding symptoms should be based upon the clinical situation and depends on the inhibitor characteristics against human and porcine factor VIII. Immunosuppression usually does not significantly affect the disappearance of the factor VIII inhibitor antibody. "
3.	von Willebrand Diseases (von Willebrand's Disease) 07/15/1983 - "The efficacy of high purity preparations of factor VIII complex are usually lacking effect on the bleeding time in von Willebrand's disease. " 03/01/1989 - "The authors describe a patient with von Willebrand's disease in whom pregnancy itself improved factor VIII activity, enabling performance of an epidural block for labor and delivery." 09/01/1983 - "Recent advances in characterizing and measuring the factor VIII complex have greatly improved the diagnosis of the variant forms of von Willebrand's disease. " 08/01/2008 - "Genetic studies were performed in a patient with a phenotype of von Willebrand disease (VWD) characterized by very low plasma factor VIII and VWF levels and a VWF consisting of only a dimeric band and total absence of all multimers in plasma. " 02/01/1998 - "[Ultrapure factor VIII concentrate with double virus inactivation: study of pharmacokinetics in von Willebrand's disease patients]."
4.	Neoplasms (Cancer) 11/15/2000 - "Histological and immunohistochemical studies of AdVmIL-12-treated tumors showed extensive inhibition of neovascularization and a marked decrease in factor VIII-stained endothelial cells. " 03/01/2005 - "In this study, immunohistochemical analysis of Tro-treated and Pio-treated tumors with factor VIII antibody revealed a significant reduction in blood vessel density compared to tumors in control animals, suggesting inhibition of angiogenesis. " 06/01/2015 - "Immunohistochemical study showed that the tumor cells were positive for CD31, ERG, FLI-1, CD34, factor VIII and CKpan to different extents. " 11/01/2006 - "Tumors were analyzed by light microscopy, MIB-1, and factor VIII immunohistochemical staining studies. " 02/01/2002 - "Studies of the vascularization of autochthonous rodent mammary tumors are limited in number, and the majority have used Factor VIII staining for blood vessel detection. "
5.	Hemophilia B (Haemophilia B) 10/01/1998 - "The use of dilution studies, chromogenic assays, a novel in-house enzyme-linked-immunosorbent-assay-based technique and phospholipid neutralization, demonstrated that Case 1 had a genuine factor VIII inactivator resulting in factor VIII levels of less than 1 IU/dl but no factor IX deficiency. " 05/01/2014 - "While the recent results in haemophilia B are extremely encouraging, there is, as yet, no similar data for factor VIII gene therapy. " 09/01/2011 - "The conditions result in various degrees of factor VIII or factor IX deficiency, respectively. " 12/29/1995 - "Transfected stromal cells may serve as suitable vehicles for gene delivery to correct single gene disorders in which the product of the target gene does not require stringent regulation as, for example, in the correction of Factor VIII and Factor IX deficiency. " 05/01/1995 - "Natural canine models of factor VIII and factor IX deficiency have been available for many years, and gene therapy attempts on these dogs have met with partial success. "

Related Drugs and Biologics

1.	von Willebrand Factor
2.	Factor IX (PTC)
3.	Antibodies
4.	Deamino Arginine Vasopressin (Desmopressin)
5.	prothrombin complex concentrates (PPSB)
6.	recombinant FVIIa (rFVIIa)
7.	Factor VIIa (Activated Factor VII)
8.	Cyclophosphamide (Cytoxan)
9.	human F8 protein
10.	Antigens

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Liver Transplantation
3.	Intravenous Infusions
4.	Tooth Extraction (Tooth Extractions)
5.	Bone Marrow Transplantation (Transplantation, Bone Marrow)